Pharmacy Podcast Network cover art

Pharmacy Podcast Network

Pharmacy Podcast Network

By: Pharmacy Podcast Network
Listen for free

Summary

Pharmacy Podcast Network (PPN) is the world’s largest network of podcasts dedicated to the pharmacy professional and industry insiders. Our content is about dynamic people in the pharmacy industry making a difference and delivering the best pharmacy care. We have over 40+ podcasts with thousands of interviews.

Pharmacists are the cornerstone of healthcare, and the PPN reflects that. From Community, LTC, Specialty Pharmacy to Drug Development, Government policy and DigitalHealth, we cover it all. Partner with us to connect with thousands of daily listeners and find the right pharmacist across various specialties and topics, ensuring your products and services resonate where it matters most. We build strong audio brands through Pharmacists who see patients almost 9x more than primary care.

Join the home of the O.G. Pharmacy Podcast & discover our newest development: Evidence-based Podcasting, the first CME supplement in podcast form that's truly peer-reviewed. The future of podcasting education for Providers is "Evidence-based Podcasting" (TM) and we're building a peer-review board, reach out to us: Publisher @ Pharmacy Podcast dot com.


PPN is a division of RxPR, LLC. Copyright 2026

2026 Pharmacy Podcast Network (TM)
Hygiene & Healthy Living Physical Illness & Disease Politics & Government
Episodes
  • The Truth About Unexplained Infertility with Nick Dorsey | The Holistic Pharmacy Podcast
    May 18 2026

    Today’s guest and I fundamentally agree on the basic premise of the body’s innate wisdom and capacity to heal, especially when we view it in a broader ecological context. According to him, infertility doesn't mean the body is broken; it's actually making intelligent, adaptive, and protective decisions made by the 4 foundational systems of the body that created life in the first place based on environmental conditions, resources, safety, and energy. Nick Dorsey, FDN-P, is a systems-based fertility and health educator, biochemist, and former chemistry educator who helps couples understand why fertility shuts down even when labs look normal and they're doing all the right things. With a Master's in biochemistry and over a decade teaching chemistry, physics, and environmental science, he translates complex biology into a clear understanding of how the body makes decisions. Nick’s research and experience supports that the body isn't broken, it's adapting intelligently to depletion, toxicity, and chronic stress, and symptoms like inflammation, fatigue, anxiety, gut dysfunction, and unexplained infertility are protective signals from a system in survival mode. Nick teaches health through the Four Pillars of biological readiness: the microbiome as the environmental interface, mitochondria as energy and resource allocators, minerals as the electrical and enzymatic stabilizers of physiology, and the nervous system as the regulator of safety and coherence. Rather than chasing symptoms, his work restores these systems so the body can repair, regulate, and reproduce when conditions are biologically appropriate. Functional labs reveal patterns of adaptation that explain why the body is saying not now, and what it needs next. Nick works with individuals and couples through high-touch, data-informed programs, with a long-term commitment to healthy pregnancies, births, and families across generations. He's a father of two with another on the way, both born at home, and long before biochemistry he spent most of his life teaching, coaching, and supporting children, including leading a youth ministry for kids with disabilities. Connect with Nick via: Email: Nick@functionalchemistry.com IG: @FunctionalChemistry YT: @FunctionalChemistry10

    Show More Show Less
    52 mins
  • Asembia's Specialty Pharmacy Summit 2026 Rewind | Part 2/6
    May 16 2026
    This is the Pharmacy Podcast Network's ASEMBIA 2026 rewind! We're dedicated to bringing you inside coverage of the pharmacy nation's biggest events with on the street style interviews with keynote speakers, attendees, exhibitors, and recurring guests who make each year special. This is part two of our six part series! We'd like to thank Nested Knowledge for sponsoring this episode! On this episode we interview:
    • Keith Kallmes - Nested Knowledge
    • Hannah Baxter and Andrew Rouff, MMIT - The Dedham Group
    • Heather Bonome - URAC
    • Jeremy Richardson - Gifthealth
    • Joe Depinto - McKesson
    • Johny Kello - MatchRx
    • Shawn Griffin - URAC
    Show More Show Less
    56 mins
  • U.S. Supreme Court and Generic Drugs | TWIRx
    May 15 2026
    This week, This Week in Pharmacy examines several stories shaping the business, clinical, and legal future of pharmacy practice. In TWIRx News from Pharmacy Times from Megan Maroney, PharmD, BCPP, FAAPP, focused on antidepressant use, withdrawal concerns, deprescribing, and shared decision-making. The key takeaway: patients should never stop antidepressants abruptly. Pharmacists can play a vital role in reducing stigma, educating patients, and supporting safe conversations about tapering, side effects, and long-term treatment. In health technology news, FDB research presented at the 2026 AMIA Amplify Informatics Conference found that patient-specific, risk-based medication guidance reduced pharmacy alert volume by 70% in a high-volume community pharmacy setting. The model consolidates alerts into one actionable message tied to the patient’s most relevant risk, helping reduce alert fatigue and improve workflow. Finally, we review a federal court ruling in Eli Lilly’s lawsuit against Houston-based Empower Pharmacy over compounded tirzepatide versions of Mounjaro and Zepbound. The judge dismissed key federal trademark and Texas unfair competition claims, while allowing other state claims to continue. Andy Crawford, with Keysource is back on TWIRx talking about the U.S. Supreme Court taking up Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., a case that could significantly affect generic drug competition. At issue is whether Hikma’s marketing materials and public communications around its generic version of Amarin’s fish oil-based cardiovascular drug improperly promoted a still-patented use. Hikma and the broader generic industry argue the case is about protecting “skinny label” rules, which allow generics to carve out patented indications while still bringing lower-cost medications to market. For pharmacists, the decision could influence generic availability, substitution confidence, pricing pressure, and how manufacturers communicate with providers and pharmacies. Thanks to our sponsors, CassianRx and IPC, for supporting independent pharmacy, innovation, and the future of patient-centered care.
    Show More Show Less
    22 mins
adbl_web_anon_alc_button_suppression_c
No reviews yet